China's Mindray Slides From Weak Government Sales, Increasing Pressure From Multinational Competition
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - U.S.-listed Chinese medical device maker Mindray reported disappointing Q2 results, which made street analysts downgrade full year sales guidance for 2010 to around $700 million, which represents 10 percent growth compared to previous guidance of 17 percent
You may also be interested in...
China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home
SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets
China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home
SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets
Philips Acquires Shanghai Apex, Targets Low-End Ultrasound Market In Wake Of China Healthcare Reform
SHANGHAI - Amsterdam-based Royal Philips Electronics has acquired Shanghai Apex, an ultrasound transducer provider in China, to expand Philips' low-end ultrasound product line to take advantage of the growing device market expected from China's ongoing healthcare reforms, the company announced July 28